Abstract:Abstract Background Accompanied with profound efficacy, atypical antipsychotics (AAPs) contribute to metabolic adverse effects with few effective strategies to attenuate. Serotonin 5-HT2C receptor (HTR2C) plays a critical role in hyperphagia and weight gain induced by AAPs, and expression of phosphatase tensin homolog (PTEN) in the hypothalamus also affects feeding behavior and weight change. Moreover, PTEN has a physical crosstalk between PTEN and a region in the third intracellular loop (3L4F) of the HTR2C. Tat-3L4F has the property to disrupt crosstalk between PTEN and HTR2C. This is the first study to our knowledge to investigate the effect of Tat-3L4F on olanzapine-induced metabolic abnormalities and PTEN/ phosphatidylinositol 3-kinase/protein kinase B expression in the hypothalamus in rats. Methods The effects of Tat-3L4F were investigated through measuring body weight, food intake, and blood glucose. In addition, PTEN/phosphatidylinositol 3-kinase/protein kinase B level in the hypothalamus was detected by immunofluorescence assay and western blot. Metabolites in the liver tissue were detected by liquid chromatography-mass spectrometry and analyzed by multivariate analyses and pairwise comparison. Results Our results showed that hyperphagia and weight gain were evident in the olanzapine alone–fed rats but was attenuated after Tat-3L4F treatment. In addition, oral glucose tolerance test indicated blood glucose at 120 minutes was higher in the olanzapine alone–treated group than in groups treated with vehicle and olanzapine + Tat-3L4F (10 μmol kg−1 per day). Furthermore, compared with olanzapine alone treatment, treatment with Tat-3L4F (10 μmol kg−1 per day) significantly inhibited PTEN expression in the hypothalamus. The olanzapine alone–treated group had the highest bile acid level, followed by the olanzapine with Tat-3L4F (1 μmol kg−1) group, olanzapine with Tat-3L4F (10 μmol kg−1) group, and vehicle group. Conclusions Our present results reveal that Tat-3L4F is a potential pharmacological strategy for suppressing hyperphagia and weight gain induced by olanzapine, which acts through disrupting crosstalk between HTR2C and PTEN as a result of PTEN downregulation in the hypothalamus.

Association of A2BP1 Gene Polymorphism with Olanzapine Induced Bodyweight Gain

A2BP1 Gene Polymorphisms Association with Olanzapine-Induced Weight Gain.

Factors associated with weight gain during six-month olanzapine therapy

A Novel Synthetic Interfering Peptide Tat-3L4F Attenuates Olanzapine-Induced Weight Gain Through Disrupting Crosstalk Between Serotonin Receptor 2C and Protein Phosphatase and Tensin Homolog in Rats.

Genome-Wide Association Study Suggested Theptprdpolymorphisms Were Associated with Weight Gain Effects of Atypical Antipsychotic Medications

Relationship of Antipsychotic Drug-Induced Weight Gain with the Polymorphism of Dopamine D2 Receptor Gene and Treatment Response in Schizophrenic Patients

Ethnicity-dependent Effects of Zinc Finger 804A Variant on Schizophrenia: a Systematic Review and Meta-Analysis

[No Association of -1438G/A Polymorphism in Promoter Region of 5-HT2A Receptor Gene with Antipsychotic Agent-Induced Weight Gain].

TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese

[Association of -2548G/A Functional Polymorphism in the Promoter Region of Leptin Gene with Antipsychotic Agent-Induced Weight Gain].

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients.

Association Analysis of ZNF804A (zinc Finger Protein 804A) Rs1344706 with Therapeutic Response to Atypical Antipsychotics in First-Episode Chinese Patients with Schizophrenia.

Association study of leptin gene and leptin receptor gene with antipsychotic agent-induced weight gain

Association Of The Htr2c-759c/T Polymorphism And Antipsychotic-Induced Weight Gain: A Meta-Analysis

Leptin -2548G/a Gene Polymorphism in Association with Antipsychotic-Induced Weight Gain: a Meta-Analysis Study.

No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.

Gut Microbiome Profiles May Be Related to Atypical Antipsychotic Associated Overweight in Asian Children with Psychiatric Disorder: a Preliminary Study.

Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia

Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation

Association study of the IRS-1 and IRS-2 gene with antipsychotic agent-induced weight gain

Olanzapine attenuates 5-HT2cR and GHSR1a interaction to increase orexigenic hypothalamic NPY: Implications for neuronal molecular mechanism of metabolic side effects of antipsychotics